Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Invion ( (AU:IVX) ) has provided an announcement.
Invion Limited has made significant strides in its cancer treatment trials, notably advancing its Phase I/II non-melanoma skin cancer trial and releasing promising Phase II prostate cancer trial results. The company is leveraging these developments to expand into an anogenital cancer trial, supported by a partnership with the Peter MacCallum Cancer Centre. Additionally, Invion has strengthened its scientific leadership with the appointment of Prof Rob Ramsay as a Scientific Advisor. The company’s cash position is bolstered by an agreement with The Lind Partners, ensuring financial support for its ongoing research and development efforts.
More about Invion
Invion Limited operates in the biotechnology industry, focusing on developing innovative therapies for cancer treatment using its Photosoft™ technology. The company is actively engaged in clinical trials for various cancer treatments and collaborates with industry partners to enhance its therapeutic offerings.
YTD Price Performance: 0.0%
Average Trading Volume: 1,055
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $9M
For a thorough assessment of IVX stock, go to TipRanks’ Stock Analysis page.
